+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05652335

Phase 1 Study of JNJ-79635322, a Trispecific Antibody, in Adults With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

180

Participants Needed

29

Research Sites

186 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying JNJ-79635322, a trispecific antibody, in people with relapsed or refractory multiple myeloma or those previously treated for Amyloid Light-chain AL Amyloidosis. The study aims to find the safest dose and schedule of JNJ-79635322 in a first-in-human phase 1 trial. It also evaluates the safety and tolerability of the drug at the recommended dose among different disease subgroups. Participants receive JNJ-79635322 through subcutaneous injections. The study has two parts Part 1 involves dose escalation to find the recommended phase 2 dose, and Part 2 involves dose expansion where participants receive the drug at the determined dose. The dosing is adjusted sequentially during Part 1 to identify the best regimen for further evaluation. During the study, participants are monitored closely for side effects, including dose-limiting toxicities and adverse events, for up to 2 years and 5 months. Researchers also measure laboratory values, drug levels in the blood, and the presence of anti-drug antibodies. The study assesses preliminary anticancer activity using established response criteria for multiple myeloma and AL amyloidosis. Participants are followed throughout to evaluate safety, tolerability, and treatment responses.

CONDITIONS

Brief Title

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here